Skip to main content

Table 2 Treatment outcome of the full group of 36 nodules

From: Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma

   Volume (mm3) Tg (ng/ml) VRR (%)
Patient no. Nodule no. Initial 24 months later Initial 24 months later 24 months later
1 1F 11,448 86 >300 147.0 99
2 2 259 0 6.2 4.9 100
3 919 0 6.2 4.9 100
4 1507 75 6.2 4.9 95
3 5 528 60 7.9 2.9 89
6 528 46 7.9 2.9 93
4 7 308 0 35.2 13.2 100
5 8 251 25 72.4 6.9 90
9 55 0 72.4 6.9 100
10 31 0 72.4 6.9 100
11 141 0 72.4 6.9 100
6 12 299 31 57.0 1.1 90
13 147 21 57.0 1.1 86
14 88 0 57.0 1.1 100
7 15 4875 293 114.8 0.7 94
16 1879 264 114.8 0.7 85
17 2327 205 114.8 0.7 91
18 94 0 114.8 0.7 100
8 19 4767 121 1.0 < 0.2 97
9 20 11 0 17.5 < 0.2 100
21 15 0 17.5 < 0.2 100
10 22G 2010 1099 8.6 < 0.2 45
23 513 377 8.6 < 0.2 26
11 24 13 0 < 0.2 < 0.2 100
12 25 1717 502 51 20.1 71
13 26H 19,225 301 119.0 60.4 98
27 2010 63 119.0 60.4 97
28 612 91 119.0 60.4 86
29 518 21 119.0 60.4 96
14 30 1281 403 21.6 6.5 69
15 31 25,017 2213 >300 90.5 91
16 32 314 0 18.2 3.2 100
17 33 452 27 0.8 0.3 94
18 34 5256 1495 >300 >300 72
35 3843 1143 >300 >300 70
36I 151 94 >300 >300 38
  1. F During the 9th month of follow-up, CEUS indicated partial re-hyper-enhancement of No. 1 nodule, so the secondary implantation was performed
  2. G US-guided puncture biopsy of No.22 nodule during follow-up indicated that there was no definite metastatic cancer was found
  3. H During the third month of follow-up, VRR and the serum Tg level reduction of No. 26 nodule were both less than 50%, so the secondary implantation was performed
  4. I Although VRR reduction of No. 36 nodules were less than 50%, and the serum Tg value > 300 ng/ml, CEUS indicated low to no enhancement of the nodule